Chengdu, China

Xianli Zhou

This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Southwest Jiaotong University. Active years: 2023.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 5.1

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Xianli Zhou

Introduction

Xianli Zhou is a prominent inventor based in Chengdu, China. He has made significant contributions to the field of medicine through his innovative research and development. With a total of 2 patents, Zhou's work focuses on the creation of novel compounds with therapeutic applications.

Latest Patents

Zhou's latest patents include a lappaconitine derivative with analgesic activity, which provides a new approach to pain management. This patent details a lappaconitine derivative of formula (I), along with its preparation and application. Additionally, he has developed a chlorin compound, which is also related to medicine. This patent describes a chlorin compound represented by formula (I), or a salt, a stereoisomer, a hydrate, a solvate, or a prodrug thereof, along with its preparation and use.

Career Highlights

Xianli Zhou is affiliated with Southwest Jiaotong University, where he conducts his research and contributes to the academic community. His work has garnered attention for its potential impact on medical treatments and drug development.

Collaborations

Zhou collaborates with notable colleagues, including Shuai Huang and Feng Gao, who contribute to his research endeavors. Their combined expertise enhances the innovative potential of their projects.

Conclusion

Xianli Zhou's contributions to the field of medicine through his patents and research at Southwest Jiaotong University highlight his role as a key innovator. His work continues to pave the way for advancements in therapeutic compounds.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…